shutterstock_1576424071_explode
Explode / Shutterstock.com
20 November 2020AmericasRory O'Neill

Medicure and Nexus agree Aggrastat generic licence

US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
19 June 2017   The US Court of Appeals for the Federal Circuit has affirmed a district court’s ruling in a dispute over diagnostic tests for cardiovascular diseases.
Americas
20 February 2017   Novartis has finalised its agreement with biopharmaceutical company Ionis Pharmaceuticals and its wholly-owned subsidiary Akcea Therapeutics to develop and commercialise therapies for cardiovascular disorders.
Americas
19 August 2021   Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.

More on this story

Americas
19 June 2017   The US Court of Appeals for the Federal Circuit has affirmed a district court’s ruling in a dispute over diagnostic tests for cardiovascular diseases.
Americas
20 February 2017   Novartis has finalised its agreement with biopharmaceutical company Ionis Pharmaceuticals and its wholly-owned subsidiary Akcea Therapeutics to develop and commercialise therapies for cardiovascular disorders.
Americas
19 August 2021   Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.

More on this story

Americas
19 June 2017   The US Court of Appeals for the Federal Circuit has affirmed a district court’s ruling in a dispute over diagnostic tests for cardiovascular diseases.
Americas
20 February 2017   Novartis has finalised its agreement with biopharmaceutical company Ionis Pharmaceuticals and its wholly-owned subsidiary Akcea Therapeutics to develop and commercialise therapies for cardiovascular disorders.
Americas
19 August 2021   Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.